Literature DB >> 10505099

Nitroreductase-mediated cell ablation is very rapid and mediated by a p53-independent apoptotic pathway.

W Cui1, B Gusterson, A J Clark.   

Abstract

Nitroreductase (NTR)-mediated selective cell ablation using the prodrug CB1954 has been achieved in vivo by targeting the nitroreductase gene to the luminal cells of the mammary gland in transgenic mice. We report that the cell ablation occurs very rapidly, starting as early as 7 h after administration of the prodrug. By cross-breeding the BLG-NTR transgenic mice to a p53-deficient mouse strain, we have generated BLG-NTR transgenic mice on a p53 null background and tested NTR-mediated cell ablation in these mice. The transgenic mice lacking a functional p53 gene showed cell ablation at a similar level compared with p53 wild-type transgenic mice, showing that functional p53 is not required for CB1954-NTR mediated cell death. These results provide further support for using this system in anti-cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10505099     DOI: 10.1038/sj.gt.3300873

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  9 in total

1.  Targeted ablation of beta cells in the embryonic zebrafish pancreas using E. coli nitroreductase.

Authors:  Harshan Pisharath; Jerry M Rhee; Michelle A Swanson; Steven D Leach; Michael J Parsons
Journal:  Mech Dev       Date:  2006-12-08       Impact factor: 1.882

2.  Immunomodulation-accelerated neuronal regeneration following selective rod photoreceptor cell ablation in the zebrafish retina.

Authors:  David T White; Sumitra Sengupta; Meera T Saxena; Qingguo Xu; Justin Hanes; Ding Ding; Hongkai Ji; Jeff S Mumm
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-17       Impact factor: 11.205

3.  Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy.

Authors:  Alan E Bilsland; Aileen Fletcher-Monaghan; W Nicol Keith
Journal:  Neoplasia       Date:  2005-11       Impact factor: 5.715

4.  Establishment of a transgenic zebrafish line for superficial skin ablation and functional validation of apoptosis modulators in vivo.

Authors:  Chi-Fang Chen; Che-Yu Chu; Te-Hao Chen; Shyh-Jye Lee; Chia-Ning Shen; Chung-Der Hsiao
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

5.  Precise spatio-temporal control of rapid optogenetic cell ablation with mem-KillerRed in Zebrafish.

Authors:  C Buckley; M T Carvalho; L K Young; S A Rider; C McFadden; C Berlage; R F Verdon; J M Taylor; J M Girkin; J J Mullins
Journal:  Sci Rep       Date:  2017-07-11       Impact factor: 4.379

6.  A mammalianized synthetic nitroreductase gene for high-level expression.

Authors:  Maik Grohmann; Nils Paulmann; Sebastian Fleischhauer; Jakob Vowinckel; Josef Priller; Diego J Walther
Journal:  BMC Cancer       Date:  2009-08-27       Impact factor: 4.430

7.  Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo.

Authors:  J Theys; O Pennington; L Dubois; G Anlezark; T Vaughan; A Mengesha; W Landuyt; J Anné; P J Burke; P Dûrre; B G Wouters; N P Minton; P Lambin
Journal:  Br J Cancer       Date:  2006-10-03       Impact factor: 7.640

8.  Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo.

Authors:  John T Heap; Jan Theys; Muhammad Ehsaan; Aleksandra M Kubiak; Ludwig Dubois; Kim Paesmans; Lieve Van Mellaert; Richard Knox; Sarah A Kuehne; Phillipe Lambin; Nigel P Minton
Journal:  Oncotarget       Date:  2014-04-15

Review 9.  Bystander or no bystander for gene directed enzyme prodrug therapy.

Authors:  Gabi U Dachs; Michelle A Hunt; Sophie Syddall; Dean C Singleton; Adam V Patterson
Journal:  Molecules       Date:  2009-11-10       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.